TrialCancer immunology, immunotherapy : CII2026
Phase II study of 1st-line durvalumab and platinum-etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC).
Elizabeth Dudnik et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.